Objectives: Deceased donor renal transplant is an accepted treatment for patients with end-stage renal disease. We retrospectively analyzed urological and surgical complications and outcomes in our series.
Materials And Methods: Since 2016, we have performed 263 renal transplants at the Gazi University Transplantation Center, Ankara, and 92 of these were from deceased donors. We retrospectively analyzed outcomes of these 92 deceased donor transplants from our database records. There were 45 female and 47 male recipients, and 20 were pediatric recipients. Mean recipient and donor ages were 36 ± 14 and 38 ± 18 years old, respectively. Immunosuppression therapy consisted of steroids, mycophenolate, and calcineurin inhibitors. Induction therapy was 20 mg basiliximab (Simulect) on day 0 and day 4. Antithymocyte globulin (2 mg∕kg) was used in steroid-resistant acute rejection cases.
Results: There were 13 surgical complications (14.1%) after 92 consecutive deceased donor renal transplants, and 4 of these were classified as miscellaneous surgical complications. Four of 9 cases were early, and the rest were classified as late complications. Postoperative early complications were bleeding (n = 2), urine leak (n = 1), and renal artery thrombosis (n = 1). Lymphoceles (n = 4) and urine leak (n = 1) occurred as late complications. Postoperative median follow-up was 78 months, during which 11 grafts (12%) were lost and 7 patients (7.6%) died from sepsis (n = 4), myocardial infarction, aortic dissection, and fungal pneumonia. No patients died from any surgical complications. The 1-year, 5-year, and 10-year survival rates of patients were 98%, 94%, and 94% and for grafts were 97%, 94%, and 88%, respectively.
Conclusion: Despite the limited number of deceased donor organs, improvements of surgical techniques at our center have facilitated success with deceased donor renal transplant at rates similar to other successful centers in the world.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.6002/ect.2020.0554 | DOI Listing |
Nephrol Nurs J
January 2025
Kidney Transplant Coordinator, Atrium Health, Carolinas Medical Center in Charlotte, NC.
Patients in need of a kidney transplant have the option of receiving a kidney from a living donor or a deceased donor. Patients in the United States who do not have an available living donor typically wait on the deceased donor waiting list for an average of three to five years, although some patients may wait longer. The waiting list is very complex and intended to allocate kidneys in a fair and equitable manner.
View Article and Find Full Text PDFJ Clin Exp Hepatol
December 2024
Department of HPB Surgery and Liver Transplant, Sir H. N. Reliance Foundation Hospital, Mumbai, India.
Narra J
December 2024
Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
Transplant renal artery stenosis (TRAS) is a serious complication of renal transplantation, with its prevalence and associated factors remaining inconclusive. The aim of this study was to assess the global prevalence and risk factors associated with TRAS incidence in renal transplant recipients. We conducted a meta-analysis by collecting data on the prevalence and factors associated with TRAS from articles in Scopus, Embase, and PubMed.
View Article and Find Full Text PDFMalar J
January 2025
Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Background: Emodepside is an anthelmintic used in veterinary medicine that is currently under investigation in human clinical trials for the treatment of soil-transmitted helminths and possibly Onchocerca volvulus. Emodepside targets the calcium-activated voltage-gated potassium slowpoke 1 (SLO-1) channels of presynaptic nerves of pharynx and body wall muscle cells of nematodes leading to paralysis, reduced locomotion and egg laying, starvation, and death. Emodepside also has activity against Drosophila melanogaster SLO-1 channels.
View Article and Find Full Text PDFApolipoprotein E (APOE) has multiple functions in metabolism and immunoregulation. Its common germline variants APOE2, APOE3 and APOE4 give rise to three functionally distinct gene products. Previous studies reported yin-yang roles of APOE2 and APOE4 in immunological processes, but their effects in hematopoietic stem cell transplantation (HSCT) have never been studied.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!